Principal Financial Group
CKPT

Principal Financial Group’s Checkpoint Therapeutics CKPT Stock Holding History

Principal Financial Group’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,136
Closed -$36K – 2609
2021
Q1 		$36K Sell
1,136
-178
-14% -$5.97K ﹤0.01% 2469
2020
Q4 		$35K Buy
+1,314
New +$33.3K ﹤0.01% 2402

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Principal Financial Group's CKPT Position: Q2 2021 in Review

Principal Financial Group sold out of Checkpoint Therapeutics (CKPT) in Q2 2021, closing a stake of 1,136 shares — an estimated $36K sold.

Principal Financial Group first reported a position in CKPT in Q4 2020 and held it in 2 quarters. The position peaked at $36K in Q1 2021. 69 funds tracked by Wall St. Rank hold CKPT as of Q2 2021.

  • Principal Financial Group reported no remaining Checkpoint Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Principal Financial Group sold 1,136 Checkpoint Therapeutics shares in Q2 2021, an estimated $36K.
  • Principal Financial Group first reported a position in Checkpoint Therapeutics in Q4 2020 and held it in 2 quarters.
  • Principal Financial Group's Checkpoint Therapeutics position peaked at $36K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2021.

Based on Principal Financial Group's 13F filing for Q2 2021, filed 10 Aug 2021.